A randomized dose-response trial of citicoline in acute ischemic stroke patients

Wayne Clark, S. J. Warach, L. C. Pettigrew, R. E. Gammans, L. A. Sabounjian

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non- US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group end the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had s favorable outcome on the Barthel Index at 90 days. There were no drug- related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.

Original languageEnglish (US)
Pages (from-to)671-678
Number of pages8
JournalNeurology
Volume49
Issue number3
StatePublished - Sep 1997

Fingerprint

Cytidine Diphosphate Choline
Stroke
National Institutes of Health (U.S.)
Therapeutics
Neurologic Manifestations
Phosphatidylcholines
Cognition
Nervous System
Animal Models
Placebos
Cell Membrane
Outcome Assessment (Health Care)
Clinical Trials
Weights and Measures

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Clark, W., Warach, S. J., Pettigrew, L. C., Gammans, R. E., & Sabounjian, L. A. (1997). A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology, 49(3), 671-678.

A randomized dose-response trial of citicoline in acute ischemic stroke patients. / Clark, Wayne; Warach, S. J.; Pettigrew, L. C.; Gammans, R. E.; Sabounjian, L. A.

In: Neurology, Vol. 49, No. 3, 09.1997, p. 671-678.

Research output: Contribution to journalArticle

Clark, W, Warach, SJ, Pettigrew, LC, Gammans, RE & Sabounjian, LA 1997, 'A randomized dose-response trial of citicoline in acute ischemic stroke patients', Neurology, vol. 49, no. 3, pp. 671-678.
Clark W, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 1997 Sep;49(3):671-678.
Clark, Wayne ; Warach, S. J. ; Pettigrew, L. C. ; Gammans, R. E. ; Sabounjian, L. A. / A randomized dose-response trial of citicoline in acute ischemic stroke patients. In: Neurology. 1997 ; Vol. 49, No. 3. pp. 671-678.
@article{649f0313257244e499b1b75e678974c5,
title = "A randomized dose-response trial of citicoline in acute ischemic stroke patients",
abstract = "Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non- US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group end the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had s favorable outcome on the Barthel Index at 90 days. There were no drug- related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.",
author = "Wayne Clark and Warach, {S. J.} and Pettigrew, {L. C.} and Gammans, {R. E.} and Sabounjian, {L. A.}",
year = "1997",
month = "9",
language = "English (US)",
volume = "49",
pages = "671--678",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A randomized dose-response trial of citicoline in acute ischemic stroke patients

AU - Clark, Wayne

AU - Warach, S. J.

AU - Pettigrew, L. C.

AU - Gammans, R. E.

AU - Sabounjian, L. A.

PY - 1997/9

Y1 - 1997/9

N2 - Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non- US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group end the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had s favorable outcome on the Barthel Index at 90 days. There were no drug- related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.

AB - Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an important component of the neural cell membrane. It has been shown to produce beneficial effects in both animal models and non- US clinical stroke trials. This study comprised a randomized (3 doses of citicoline to 1 placebo), vehicle-controlled, double-blind trial at 21 US centers. Treatment was to be started within 24 hours of stroke onset and was continued orally for 6 weeks. Final outcome assessments were at 12 weeks. Two hundred fifty-nine patients were enrolled, with approximately 65 in each of the four groups. Mean time from stroke onset to treatment was 14.5 hours, and there were no significant differences in baseline characteristics between the four groups except for patient weight. A significant difference between the groups, favoring citicoline treatment, was seen in terms of functional outcome as measured by the Barthel Index and Rankin scale, neurologic evaluation as measured by the National Institutes of Health (NIH) stroke scale, and cognitive function as measured by the Mini Mental Status Examination. When the baseline NIH stroke scale was used as a covariate, both the 500-mg citicoline group end the 2,000-mg citicoline group had a significant improvement in terms of the percent of patients who had s favorable outcome on the Barthel Index at 90 days. There were no drug- related serious adverse events or deaths in this study. This study suggests that oral citicoline can be used safely with minimal side effects in acute stroke treatment. Citicoline appears to improve functional outcome and reduce neurologic deficit with 500 mg of citicoline appearing to be the optimal dose.

UR - http://www.scopus.com/inward/record.url?scp=0030760430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030760430&partnerID=8YFLogxK

M3 - Article

C2 - 9305321

AN - SCOPUS:0030760430

VL - 49

SP - 671

EP - 678

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -